Sparsentan Fails In Phase III FSGS Study, But Travere Assessing Path To Approval
No Readthrough Likely In Confirmatory IgAN Trial
Travere’s drug, approved as Filspari for immunoglobulin A nephropathy, missed its eGFR primary endpoints in focal segmental glomerulosclerosis but showed meaningful improvement in proteinuria.
